drugset / Trial / NCT02710240

Indocyanine Green for Central Nervous System Tumors

NCT02710240

Phase 1/2 Completed 336 enrolled Abramson Cancer Center at Penn Medicine
NaSingle-groupOpen-labelDiagnostic

Summary

This study is a single center, open-label, two-part study to assess image guided surgery of intramolecular imaging in nervous system tumors. Subjects with a diagnosis of a resectable nervous system tumor who are at risk of recurrence are included. The primary goal is to observe what tissues fluoresce in the OR, and then to identify if that tissue is cancerous/tumor or normal when the histopathology is performed.

Timeline

Start
2015-06-10
Primary completion
2020-02-04
Completion
2020-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 25 mg Intravenous